Vimta Labs Limited reported a total income of Rs. 911 million for Q3 FY25, reflecting a 21.1% year-on-year growth, and an EBITDA margin of 37.6%. The announcement also noted the successful transfer of its Diagnostic and Pathological services business to Thyrocare Technologies completed on October 11, 2024.